I agree, ou. I too want to just see a "continue" (much as all of us would love to see Flip's hypothesis proven correct) and have it out of the way. It is an overhang on the stock, no question about it. I'm not sure about the immediate impact of a "continue" on the stock price, though. The bashers would come out with their if-it-was-only-a-continue-they-what-took-so-long whines, but if NWBO can counter that with the progress they've been making on DCVax-L trial and Hospital Exemption Programme, and hints at a some read-out of initial data from DCVax-Direct, then I think they will be swept aside quickly and the share price can glide into double digits, heading into ASCO.
Market Data 
Markets 
AI
